Humana Inc hits 5-day high amid kickback allegations.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 03 Dec 25
Source: Benzinga
Humana Inc's stock rose by 5.02%, reaching a 5-day high amid ongoing investigations into alleged illegal kickbacks to insurance brokers.
The allegations involve up to $250 million in kickbacks, raising concerns about the company's reputation and potential legal liabilities. Senior executives are reportedly implicated, which could further impact shareholder confidence.
As the investigation unfolds, the market is reacting sensitively to these developments, reflecting investor concerns about Humana's future outlook and governance practices.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 290.39 USD with a low forecast of 231.00 USD and a high forecast of 344.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 196.670
Low
231.00
Averages
290.39
High
344.00
Current: 196.670
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
